<DOC>
	<DOCNO>NCT02391259</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled , sequential rise single-dose study approximately 56 subject SLE enrol 7 dosing cohort</brief_summary>
	<brief_title>A Study Evaluate Safety , Pharmacokinetics Pharmacodynamics AMG 557 Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Diagnosis SLE positive ANA Stable disease change SLE therapy within previous 30 day BMI 18 38 kg/m2 Have sign symptom viral , bacterial fungal infection within 30 day study randomization Evidence renal disease liver disease Any history granulomatous disease include autoimmune granulomatous vasculitis sarcoidosis Prior administration biologic primarily target immune system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>